What is the MMRC®?
[cm_tooltip_parse]The Multiple Myeloma Research Consortium® (MMRC®) brings together the best cancer centers in the world to accelerate clinical trials and drive results for patients. Top myeloma researchers and world-renowned academic institutions are aggressively investigating many cutting-edge treatments — including molecular targets, immune agents and novel agents.
Leveraging a collaborative research model, the MMRC has conducted nearly 100 Phase I and II trials, enrolling thousands of patients to date. Everything we do focuses on accelerating discovery and rapidly advancing medicine. [/cm_tooltip_parse]
Meet Dr. Cho, Chief Medical Officer
[cm_tooltip_parse]Hearn Jay Cho, MD, PhD, is the MMRF’s Chief Medical Officer and head of the MMRC. He leads 22 research centers in advancing treatment options for multiple myeloma patients. Dr. Cho is also responsible for the MMRF’s clinical research strategy and accelerating drug development programs. He is an Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai and an Attending Physician with the Multiple Myeloma Service at the Mt. Sinai Tisch Cancer Institute.[/cm_tooltip_parse]
The MMRC pipeline
[cm_tooltip_parse]The MMRC and its research collaborators are committed to excellence in multiple myeloma clinical trials. With streamlined communications, quality trial conduct and a patient-driven research model that demonstrates faster trial starts and enrollment, the MMRC is a recognized multiple myeloma center of excellence.[/cm_tooltip_parse]
Trials for newly diagnosed patients
Trials for relapsed refractory patients
Feature trial: MyDRUG
[cm_tooltip_parse]MyDRUG (Myeloma – Developing Regimens Using Genomics) is a groundbreaking cancer clinical trial testing several new treatments for patients with high-risk multiple myeloma. MyDRUG is testing drugs designed specifically for each myeloma subtype, accelerating the development of novel tailored treatments.[/cm_tooltip_parse]
Hearn Jay Cho, MD, PhD.
Associate Professor of Medicine Hematology & Medical Oncology,
Multiple Myeloma Center of Excellence
Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai
Jesus G. Berdeja, MD
Ajai Chari, MD
Amrita Y. Krishnan, MD
Director, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Medical Center Duarte, California
Ajay Nooka, MD MPH, FACP
Nina Shah, MD
Saad Z. Usmani, MD FACP
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute, Charlotte, North Carolina
The MMRC is proud to partner with distinguished multiple myeloma researchers and world-renowned academic institutions to collaborate on accelerating clinical developments in multiple myeloma treatments.